Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer.

Lycera develops small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer.

Lycera was founded in 2006 and is headquartered in Ann Arbor, Michigan with locations in New York, New York; and Plymouth Meeting, Pennsylvania.

Lycera's approach builds on an in-depth understanding of the orchestration of immune response in disease progression. When working correctly, the immune system can respond aggressively and with precise targeting to eliminate infectious pathogens or cancer cells.

Lycera offers LYC-55716, a multiple anti-tumor mechanism into a single therapeutic by modulating gene expression to reprogram immune cells for improved function, as well as decrease immunosuppressive mechanisms; and ATPase Modulators, a therapy for autoimmune diseases.

Lycera has the expertise and insight necessary to develop innovative therapies able to restore immune balance and significantly improve treatment for patients affected by these diseases around the world.

Lycera is rapidly building a portfolio of selective immune modulators with mechanisms we believe will translate into improved outcomes for patients.


Lycera is backed by EDF Ventures, InterWest Partners, ARCH Venture Partners, & Clarus Ventures. The company has raised a total of $74.9M in funding to date.



  • Year founded: 2006
  • Funding Info: $74.9M in 5 Funding Rounds (Last Funding Type: Series B)
  • Yearly Revenue: $10M-$20M (2018)
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Ann Arbor
  • State: Michigan
  • Country: United States
Related businesses